Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

727
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
727
Principles of Drug Action01:24

Principles of Drug Action

6.0K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.0K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

152
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
152
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

997
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
997

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Targeting the Crosstalk Between Metabolism and Chronic Inflammation: In Silico Multitargeting Drug Design Approach for Cardiometabolic Syndrome.

Biomedicines·2026
Same author

Advancing Accurate Quantification of Protein-Ligand Interactions: Differential Scanning Calorimetry as a Precision Screening Tool Using BCL-2 as a Model System.

ChemMedChem·2026
Same author

Correction: Petsas et al. Protein-Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection. <i>Molecules</i> 2025, <i>30</i>, 4240.

Molecules (Basel, Switzerland)·2026
Same author

Structural and Computational Insights into the Angiotensin II Type 1 Receptor: Advances in Antagonist Design and Implications for Hypertension Therapy (2020-2024).

Biomolecules·2026
Same author

Isolation and Biophysical Characterization of Lipoxygenase-1 from Soybean Seed, a Versatile Biocatalyst for Industrial Applications.

Biomolecules·2026
Same author

Recent Advances in Dual COX/LOX Inhibitor Design (2020-2024): Establishing "<i>The Rule of Four for Inflammation</i>".

Life (Basel, Switzerland)·2026

相关实验视频

Updated: Jul 7, 2025

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

3.4K

奎尔塞丁:一种潜在的多动态药物

Nikitas Georgiou1, Margarita Georgia Kakava2, Efthymios Alexandros Routsi1,3

  • 1Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece.

Molecules (Basel, Switzerland)
|December 23, 2023
PubMed
概括

奎尔赛丁是一种天然的黄类化合物,具有抗癌和抗炎功效. 将奎尔素封装在宏分子中可以提高其生物可用性和制药效率,用于药物开发.

关键词:
黄类化合物 黄类化合物文素 (Quercetin) 是一种文素.

更多相关视频

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.5K
Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans
09:18

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans

Published on: September 7, 2021

2.9K

相关实验视频

Last Updated: Jul 7, 2025

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

3.4K
Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.5K
Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans
09:18

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans

Published on: September 7, 2021

2.9K

科学领域:

  • 药理学和天然产品化学化学
  • 药物输送系统 药物输送系统
  • 纳米技术在医学中的应用

背景情况:

  • 自然产品,特别是素等黄类药物,作为潜在的治疗药物被广泛研究.
  • 奎思具有显著的抗癌,抗炎和抗菌特性.
  • 奎尔丁的主要局限性是其生物可用性较差和溶解性较低,阻碍了其制药应用.

研究的目的:

  • 审查奎尔塞丁的有益药物效应.
  • 讨论与氨酸的生物可用性和溶解性相关的挑战.
  • 探索封装策略,包括新的纳米技术方法,以提高奎尔丁的疗效.

主要方法:

  • 关于奎尔丁药理作用的文献综述.
  • 对瑞丁现有的封装技术进行分析.
  • 建议和讨论使用纳米技术的新封装方法.

主要成果:

  • 奎尔氨酸表现出广泛的有益生物活性,包括抗癌,抗炎和抗菌作用.
  • 大分子封装显著提高了奎尔丁的生物可用性和可溶性.
  • 基于纳米技术的输送系统为提高奎尔塞丁药物效率提供了有希望的途径.

结论:

  • 奎尔是一种有前途的天然化合物,具有多种治疗潜力.
  • 通过先进的封装技术克服低生物可用性对于实现奎尔丁的全部药用价值至关重要.
  • 新型纳米载体系统在优化基于奎尔素的药物输送和疗效方面取得了重大进展.